France / United States / United Kingdom / Scotland / /
Currency
GBP / USD / /
Event
FDA Phase / /
Facility
University of Glasgow The / Institute of Neurological Sciences / University of Glasgow / Glasgow’s Southern General Hospital / University of Glasgow Stuart Forsyth / Southern General Hospital / /
IndustryTerm
treatment for blindness-causing diseases / multi-site / brain imaging techniques / therapies for significant disease / stem cell technologies / platform technology / cell selection technologies / manufacturing scale-up / clinical and commercial-grade cell therapy product / stroke services / eventual marketed product / social care systems / clinical site / early imaging data / therapy for stroke / /
Greater Glasgow and Clyde NHS Board / Buchanan Mark Court / University of Glasgow / Glasgow Experimental MRI Centre / Acute Stroke Unit / Medical Research Council / Division of Clinical Neurosciences / UK Stroke Association / Glasgow’s Southern General Hospital / Institute of Neurological Sciences / Southern General Hospital / /
Person
Michael Hunt / Keith Muir / Christopher Golden / Fiona Henson / John Sinden / Andy Roberts / Sophie Cowles / / /
Position
Principal Investigator / Broker / Chief Executive Officer / Chief Scientific Officer / Professor / Professor of Clinical Imaging / /
Petra Diamonds Limited (“the Company”)